Several cancer therapies consist of antibodies that engage CD16a to trigger cellular immunity, such as cetuximab that binds and blocks epidermal growth factor receptor (EGFR) in tumor cells and induces ADCC2. This evidence concerns the gene FCGR3A and cancer.